Skip to Main Navigation Skip to Content
Collaborative global initiatives in science

Main Content

Scientific Advisory Board

Our Scientific Advisory Board provides critical guidance and direction for our Foundation.

This dedicated, evolving group of opinion leaders, shares our commitment to improving and facilitating the flow of medical and scientific research in the field of infectious disease throughout the developed and developing worlds.

Our Scientific Advisory Board guides us in shaping our Foundation’s initiatives, helps us determine and develop new programs and directs us to ground breaking research and health crises around the globe.

These advisors also review submissions from Macrae Foundation Fellows, recommend and source Mentors for our Fellows and institute new partnerships for our Lab Exchange Program.

Board Members:

Menno D. de Jong, MD, PhD, FRCP Edin

After Medical School at the University of Amsterdam (1991), and PhD research on HIV treatment (1996), Menno de Jong specialized in Clinical Microbiology at the Academic Medical Center, University of Amsterdam (2000). He worked as consultant clinical microbiologist at the Leiden University Medical Center (2000-2001) and the Academic Medical Center, University of Amsterdam (2001-2003). In 2003, he moved to Ho Chi Minh City, Vietnam, where he set up and headed the Laboratory of Virology at the Oxford University Clinical Research Unit (OUCRU), Hospital for Tropical Diseases, and where he became involved in clinical and virological research on avian and human influenza. Whilst remaining senior faculty member at OUCRU, Dr. de Jong has moved back to Amsterdam in August 2008, where he was appointed professor in Clinical Virology and Head of the Department of Medical Microbiology at the Academic Medical Center, University of Amsterdam.

Sebastian Johnston, M.D., PhD

Sebastian L. Johnston: is Professor of Respiratory Medicine at the National Heart and Lung Institute, Imperial College London, United Kingdom. He is Director of the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma. His main disciplines are Pulmonology, Allergy and Immunology and Infectious Disease. He qualified in Medicine from Guy’s Hospital in 1982, gained his PhD from Southampton University in 1993, was elected Fellow of the Royal College of Physicians in 1999 and Fellow of the Society of Biology in 2011. He is past Chairman of the Infection Group in the European Respiratory Society and the Asthma Section of the European Academy of Allergy and Clinical Immunology. He was Editor of Thorax from 2003-2010. His main research interest has been the role of respiratory viruses and their interaction with asthma and COPD and in particular, the association of virus infections with acute exacerbations of asthma and COPD. Other major interests include RSV bronchiolitis, antiviral immunity, immune regulation and susceptibility to viral infection, the contribution of viral infection/colonisation to chronic stable airway disease, the molecular mechanisms of virus induced inflammation and anti viral therapies.

Arnold Monto, MD

Arnold S. Monto is the Thomas Francis Jr. Collegiate Professor of Epidemiology at the University of Michigan School of Public Health in Ann Arbor. The major focus of his work has been the epidemiology, prevention and treatment of acute infections in the individual and the community. Respiratory infections, in particular influenza, have been a major interest, with special reference to the evaluation of vaccines in various populations and the assessment of the value of antivirals. He has worked on these issues in tropical as well as temperate regions. Dr. Monto led the studies of respiratory infection in Tecumseh, MI, a landmark study of infection in the community. He has studied various approaches to influenza vaccine use, particularly to control transmission of the virus in the community and in nursing homes.

Dr. Monto is involved in assessing the efficacy of various types of influenza vaccine in prophylaxis and neuraminidase inhibitors and other compounds in prophylaxis and therapy of influenza, including implications of antiviral resistance. He now heads an observational study of effectiveness of influenza vaccines in various settings. His recent activities have included evaluation of face masks and hand hygiene in the control of influenza transmission and determination of efficacy of the traditional inactivated and live attenuated influenza vaccines. He works extensively with national and international organizations on issues related to pandemic preparedness. He has been a member of the Pulmonary Diseases Advisory Committee and the National Allergy and Infectious Disease Advisory Council of the US National Institutes of Health. He is a past president of the American Epidemiological Society and the 2009 recipient of the Alexander Fleming Award of the Infectious Diseases Society of America for lifetime achievement. Dr. Monto was a member of the Emergency Committee making recommendations to the World Health Organization during the past influenza pandemic.

Albert D.M.E. Osterhaus, PhD

Professor Dr. A.D.M.E. (Ab) Osterhaus started his career in Utrecht (The Netherlands) where he graduated with distinction at the faculty of veterinary sciences. In 1978 he received his PhD degree with Prof. Dr. M.C. Horzinek. He then moved to the RIVM in Bilthoven, where he would stay until 1994. Since then, he has been working at Erasmus MC in Rotterdam. Thirty years of experience in animal and human virology have resulted in a specific interest in viruses that ordinarily affect only animals but that can cross the species barrier. Osterhaus is now a leading authority, able to identify dangerous and elusive new viruses with speed and precision. Osterhaus’ team reacted with exceptional speed to the SARS outbreak of 2003 when they, in a collaborative WHO effort, proved that a coronavirus was the causative agent. This allowed them to effectively diagnose and isolate suspected cases immediately, which effectively brought SARS under control and countless lives were saved. In 1997 Osterhaus and his team silenced skeptics when they proved that Avian Influenza (H5N1) could be transmitted to humans. Osterhaus has advised and helped health authorities to prepare for potential outbreaks, and, as an individual, has campaigned determinedly for awareness, calling for a global taskforce to prepare for and combat viruses such as H5N1. Throughout his professional career Osterhaus and his team have identified around twenty ‘new’ viruses of humans (such as the human metapneumovirus, hMPV and a novel human coronavirus, HcoV-NL) in animals as well as countless new possible hosts. His research includes studies on virus reservoirs in wildlife, mechanisms of transmission and pathogenesis of zoonotic viruses. In addition, innovative fundamental research on the natural and vaccine-induced immune response and on antiviral drugs is performed to combat the threat posed by human and animal virus infections. As part of his tireless active interest in public health, Osterhaus has acted as Ph.D. mentor for over 50 students, authored over 1000 academic articles, created biotech companies and held several editorial positions. The continuous and groundbreaking work of the so-called ‘virus hunter’ has helped identify and control the spread of deadly viruses and will continue to do so, saving countless lives and changing the face of world health today.

J.S.M. Peiris, PhD

Malik Peiris is currently Professor: Chair in Virology, School of Public Health at The University of Hong Kong and Director of the Centre of Influenza Research. His current research focuses on the virology, evolution, pathogenesis and epidemiology of animal and human influenza and other respiratory viral infections. He has a particular interest in emerging viral infections and in virus infections at the animal-human interface. In 2003, Dr. Peiris played a key role in the discovery that a novel coronavirus was the cause of SARS. He was elected a Fellow of the Royal Society of London in 2006, awarded the Legion d’Honneur of the Republic of France in 2007 and the Silver Bauhinia Star of the Hong Kong Special Administrative Region in 2008.